Core Viewpoint - Goldman Sachs reports that Haijia Medical (06078) has experienced a significant decline in both revenue and adjusted net profit for the first half of the year, consistent with previous profit warnings, reflecting ongoing pressures from industry policy reforms such as DRG/DIP payment reforms and volume-based procurement [1] Financial Performance - Haijia Medical's revenue and adjusted net profit have both declined significantly during the period, indicating the impact of industry-wide policy reforms [1] - The company's earnings forecasts for the fiscal years 2025 to 2027 have been reduced by 8.3%, 11%, and 14% respectively, due to the continued pressure from these policy reforms [1] Target Price and Rating - The target price for Haijia Medical has been lowered from HKD 21.3 to HKD 19.1, while maintaining a "Buy" rating [1]